08:57 AM EDT, 03/11/2024 (MT Newswires) -- Viatris ( VTRS ) said Monday that Mapi Phrama has received a complete response letter from the US Food and Drug Administration regarding their new drug application for GA Depot 40 mg as a treatment for multiple sclerosis.

The companies said they are reviewing the letter's content and will determine their next steps, adding that they continue to believe in the product's potential to advance new treatment for multiple sclerosis patients.

The letter won't affect Viatris' ( VTRS ) financial guidance for 2024, according to the companies.

Price: 12.22, Change: -0.04, Percent Change: -0.33